Casey Tansey Buys 15,821 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 15,821 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $11.66 per share, with a total value of $184,472.86. Following the purchase, the director directly owned 284,725 shares in the company, valued at $3,319,893.50. This represents a 5.88% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mobia Medical Stock Performance

Shares of Mobia Medical stock opened at $11.73 on Wednesday. The company has a quick ratio of 12.80, a current ratio of 13.28 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $12.40. Mobia Medical, Inc. has a 52 week low of $10.19 and a 52 week high of $15.29. The firm has a market capitalization of $390.49 million and a PE ratio of -0.61.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The company’s quarterly revenue was up 102.4% compared to the same quarter last year. Research analysts forecast that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MOBI. The Goldman Sachs Group assumed coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Wolfe Research started coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set an “outperform” rating on the stock. Bank of America started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective for the company. Finally, Zacks Research upgraded shares of Mobia Medical to a “hold” rating in a report on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.